Apnimed to Participate in Upcoming July Investor Conferences
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that management will be participating in the following investor conferences taking place in July. https://mma.prnewswire.com/media/2495448/Apnimed_Logo.jpg Details of Apnimed's participation are as follows: Event: Evercore's […]